This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Hyperglycaemia and Insulin Resistance in HIV Infected Patients

This study has been completed.
Information provided by:
University Medical Centre Ljubljana Identifier:
First received: June 5, 2007
Last updated: NA
Last verified: June 2007
History: No changes posted
The purpose of this study is to evaluate and compare the effects of treatment with rosiglitazone and metformin on insulin resistance in patients infected with Human Immunodeficiency Virus on stable Highly Active Antiretroviral Therapy including a Protease Inhibitor after the period of 48 weeks.

Condition Intervention
Insulin Resistance Drug: metformin, rosiglitazone

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by University Medical Centre Ljubljana:

Primary Outcome Measures:
  • fasting plasma glucose, basal insulin levels [ Time Frame: 48 weeks ]

Secondary Outcome Measures:
  • insulin resistance, beta cell function [ Time Frame: 48 week ]


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male

Inclusion Criteria:

  • documented HIV infection
  • stable Protease Inhibitor containing HAART regimen for at least 12 months
  • impaired glucose tolerance
  • elevated insulin levels (above 20 mIU/l)

Exclusion Criteria:

  • patients already taking oral hypoglycaemic treatment or insulin
  • heart failure NYHA I-IV
  • liver disease or kidney disease
  • elevated AST or ALT above 2 times upper normal range
  • elevated creatinine (above 150 mmol/l)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00483392

Department of Endocrinology, Diabetes and Metabolic diseases
Ljubljana, Slovenia, 1525
Sponsors and Collaborators
University Medical Centre Ljubljana
Study Chair: Andrej Janez, MD, PhD Department of Endocrinology, Diabetes and Metabolic Diseases, Medical Center Ljubljana, Zaloska 7, 1525 Ljubljana, Slovenia
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00483392     History of Changes
Other Study ID Numbers: J3-3545
Slovenia grant J3-3545
Study First Received: June 5, 2007
Last Updated: June 5, 2007

Keywords provided by University Medical Centre Ljubljana:
protease inhibitors

Additional relevant MeSH terms:
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on September 21, 2017